Physician profile
Venkatesan Vidi
NPI 1962673392
$16,346.73
in general payments reported to CMS, 2019-2025
45 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,183 · 2020: $1,210 · 2021: $1,503 · 2022: $1,800 · 2023: $3,960 · 2024: $3,691 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,933 · Travel and Lodging: $2,715 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,932.58 |
| Travel and Lodging | $2,714.95 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,763.06 | 2019-2025 | Xact, Gallant, Optis |
| Penumbra, INC. | $2,004.77 | 2022-2023 | Indigo System |
| Novartis Pharmaceuticals Corporation | $1,223.60 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $568.26 | 2019-2025 | Lifevest |
| Amgen INC. | $552.91 | 2019-2025 | Repatha |
| Pfizer INC. | $539.24 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $523.05 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $521.56 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $486.97 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.77 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $391.66 | 2019-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $388.14 | 2021-2025 | Onpattro, Amvuttra |
| Esperion Therapeutics, INC. | $386.83 | 2020-2024 | Nexletol |
| Novo Nordisk INC | $274.74 | 2021-2025 | Wegovy, Ozempic |
| Astellas Pharma US INC | $240.52 | 2019-2020 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $223.92 | 2024 | Barostim Neo System |
| Medtronic, INC. | $219.92 | 2022-2025 | Symplicity G3 |
| Amarin Pharma, INC. | $166.80 | 2019-2021 | |
| Philips North America LLC | $150.25 | 2020-2025 | (Ck7) Extended Holter, Extended Holter, Mcot |
| Lundbeck LLC | $138.30 | 2019-2021 | |
| Shockwave Medical, INC | $125.82 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $123.49 | 2019-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $106.91 | 2021-2023 | Arcalyst |
| Bardy Diagnostics, INC. | $95.00 | 2019-2020 | |
| Boston Scientific Corporation | $92.05 | 2023-2024 | Watchman Flx, Accolade Sr, Emblem Mri S-Icd |
| Edwards Lifesciences Corporation | $72.12 | 2019-2025 | Sapien 3 Ultra Resilia |
| Lexicon Pharmaceuticals, INC. | $52.79 | 2023-2024 | Inpefa |
| Atricure, INC. | $52.16 | 2022 | |
| Scpharmaceuticals INC. | $50.23 | 2025 | |
| Inspire Medical Systems, INC. | $49.47 | 2023-2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $48.06 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $43.14 | 2019 | |
| Vital Connect, INC | $36.42 | 2025 | Vitalpatch Rtm |
| Kestra Medical Technology Services, INC. | $35.61 | 2025 | Assure Wcd |
| G Medical Diagnostic Services, INC. | $29.29 | 2023 | Cardiac Monitoring Suite |
| Biosense Webster, INC. | $26.39 | 2023 | Carto 3 |
| Ge Healthcare | $24.27 | 2019 | |
| Cardiovascular Systems INC. | $24.22 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $18.84 | 2021 | |
| Convatec INC. | $18.77 | 2023 | |
| W. L. Gore & Associates, INC. | $16.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.53 | 2019 | |
| Angiodynamics, INC. | $11.85 | 2022 | |
| Biotronik INC. | $11.65 | 2019 | |
| Cardinal Health 200 LLC | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkatesan Vidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.